• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

AAV5 为基础的疫苗诱导小鼠呼吸道合胞病毒中和抗体反应。

Induction of neutralizing antibody responses by AAV5-based vaccine for respiratory syncytial virus in mice.

机构信息

Guangzhou National Laboratory, Guangzhou, China.

Guangzhou Medical University, Guangzhou, China.

出版信息

Front Immunol. 2024 Oct 14;15:1451433. doi: 10.3389/fimmu.2024.1451433. eCollection 2024.

DOI:10.3389/fimmu.2024.1451433
PMID:39469716
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11513327/
Abstract

INTRODUCTION

Respiratory Syncytial Virus (RSV) is a significant cause of respiratory illnesses worldwide, particularly in infants and elderly individuals. Despite the burden RSV imposes, effective preventive measures are limited. The research application of adeno-associated virus (AAV) in vaccine platforms has been expanding, and its potential in prevention and treatment has garnered much attention.

METHODS

In this study, we explored the potential application of a recombinant adeno-associated virus 5 (rAAV5) vector-based RSV vaccine, focusing on the expression of the pre-fusion (Pre-F) protein structure. Through intramuscular immunization in mice. The immunogenicity of the vaccine was evaluated in Balb/c mice immunized intramuscularly and intranasal, respectively.

RESULTS

The rAAV5-RSV-Fm vaccine demonstrated positive humoral and induced antibody titers against RSV strains A and B for up to 120 days post-immunization. Notably, intranasal administration also elicited protective antibodies. Characterization studies confirmed the ability of the vac-cine to express the Pre-F protein and its superior immunogenicity compared to that of full-length F protein.

CONCLUSION

These findings underscore the potential application of rAAV5 vector platforms in RSV vaccine development and further investigation into their protective efficacy is warranted.

摘要

简介

呼吸道合胞病毒（RSV）是全球范围内引起呼吸道疾病的重要原因，尤其是在婴儿和老年人中。尽管 RSV 造成了很大的负担，但有效的预防措施仍然有限。腺相关病毒（AAV）在疫苗平台中的研究应用正在不断扩展，其在预防和治疗方面的潜力引起了广泛关注。

方法

在这项研究中，我们探索了基于重组腺相关病毒 5（rAAV5）载体的 RSV 疫苗的潜在应用，重点关注前融合（Pre-F）蛋白结构的表达。通过肌肉内免疫接种小鼠。通过肌肉内和鼻内免疫接种 Balb/c 小鼠，评估了疫苗的免疫原性。

结果

rAAV5-RSV-Fm 疫苗显示出针对 RSV 株 A 和 B 的体液免疫和诱导抗体滴度呈阳性，免疫后长达 120 天。值得注意的是，鼻内给药也引发了保护性抗体。特征描述研究证实了疫苗表达 Pre-F 蛋白的能力及其与全长 F 蛋白相比的优越免疫原性。

结论

这些发现强调了 rAAV5 载体平台在 RSV 疫苗开发中的潜在应用，需要进一步研究其保护效力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f82f/11513327/e23a14604cc2/fimmu-15-1451433-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f82f/11513327/499fca25b87d/fimmu-15-1451433-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f82f/11513327/8b8e2024e8b1/fimmu-15-1451433-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f82f/11513327/32a750a6d2a8/fimmu-15-1451433-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f82f/11513327/ef37e944be71/fimmu-15-1451433-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f82f/11513327/e23a14604cc2/fimmu-15-1451433-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f82f/11513327/499fca25b87d/fimmu-15-1451433-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f82f/11513327/8b8e2024e8b1/fimmu-15-1451433-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f82f/11513327/32a750a6d2a8/fimmu-15-1451433-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f82f/11513327/ef37e944be71/fimmu-15-1451433-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f82f/11513327/e23a14604cc2/fimmu-15-1451433-g005.jpg

相似文献

1
Induction of neutralizing antibody responses by AAV5-based vaccine for respiratory syncytial virus in mice.AAV5 为基础的疫苗诱导小鼠呼吸道合胞病毒中和抗体反应。
Front Immunol. 2024 Oct 14;15:1451433. doi: 10.3389/fimmu.2024.1451433. eCollection 2024.
2
Development of an adenovirus-based respiratory syncytial virus vaccine: preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model.基于腺病毒的呼吸道合胞病毒疫苗的研发：在棉鼠模型中对疗效、免疫原性和增强疾病的临床前评估。
J Virol. 2014 May;88(9):5100-8. doi: 10.1128/JVI.03194-13. Epub 2014 Feb 26.
3
A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.副流感病毒载体表达呼吸道合胞病毒（RSV）融合前 F 蛋白比 RSV 更有效地增强 RSV 初次免疫。
J Virol. 2020 Dec 22;95(2). doi: 10.1128/JVI.01512-20.
4
A Respiratory Syncytial Virus Vaccine Vectored by a Stable Chimeric and Replication-Deficient Sendai Virus Protects Mice without Inducing Enhanced Disease.一种由稳定的嵌合型和复制缺陷型仙台病毒载体携带的呼吸道合胞病毒疫苗可保护小鼠，且不会引发疾病加重。
J Virol. 2017 Apr 28;91(10). doi: 10.1128/JVI.02298-16. Print 2017 May 15.
5
Parainfluenza Virus 5 Expressing Wild-Type or Prefusion Respiratory Syncytial Virus (RSV) Fusion Protein Protects Mice and Cotton Rats from RSV Challenge.表达野生型或融合前呼吸道合胞病毒（RSV）融合蛋白的副流感病毒5可保护小鼠和棉鼠免受RSV攻击。
J Virol. 2017 Sep 12;91(19). doi: 10.1128/JVI.00560-17. Print 2017 Oct 1.
6
Intranasal immunization with a helper-dependent adenoviral vector expressing the codon-optimized fusion glycoprotein of human respiratory syncytial virus elicits protective immunity in BALB/c mice.鼻腔内免疫接种表达人呼吸道合胞病毒优化密码子融合糖蛋白的辅助依赖性腺病毒载体可在 BALB/c 小鼠中引发保护性免疫。
Virol J. 2013 Jun 7;10:183. doi: 10.1186/1743-422X-10-183.
7
Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.表达呼吸道合胞病毒（RSV）融合蛋白的重组低血清流行率腺病毒载体Ad26和Ad35可诱导棉鼠对RSV感染产生保护性免疫。
Vaccine. 2015 Oct 5;33(41):5406-5414. doi: 10.1016/j.vaccine.2015.08.056. Epub 2015 Aug 28.
8
Cold-adapted influenza vaccine carrying three repeats of a respiratory syncytial virus (RSV) fusion glycoprotein epitope site protects BALB/c mice and cotton rats against RSV infection.携带呼吸道合胞病毒（RSV）融合糖蛋白表位位点三个重复序列的冷适应流感疫苗可保护BALB/c小鼠和棉鼠免受RSV感染。
Antiviral Res. 2024 Sep;229:105960. doi: 10.1016/j.antiviral.2024.105960. Epub 2024 Jul 8.
9
Mucosal Delivery of Recombinant Vesicular Stomatitis Virus Vectors Expressing Envelope Proteins of Respiratory Syncytial Virus Induces Protective Immunity in Cotton Rats.黏膜途径传递表达呼吸道合胞病毒包膜蛋白的重组水疱性口炎病毒载体诱导棉鼠产生保护性免疫。
J Virol. 2021 Feb 24;95(6). doi: 10.1128/JVI.02345-20.
10
Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years.一项评估腺病毒 26 载体编码融合前 F （Ad26.RSV.preF）的呼吸道合胞病毒疫苗在 60 岁及以上成年人中的安全性和免疫原性的 1 期研究。
J Infect Dis. 2020 Aug 17;222(6):979-988. doi: 10.1093/infdis/jiaa193.

引用本文的文献

1
Teaching an old vector new tricks: the surprising versatility of AAV vaccines.教老载体新把戏：腺相关病毒疫苗出人意料的多功能性
J Virol. 2025 Aug 19;99(8):e0073025. doi: 10.1128/jvi.00730-25. Epub 2025 Jul 14.
2
Integrated Metabolomics and Network Pharmacology to Reveal the Mechanisms of Extract Against Respiratory Syncytial Virus.整合代谢组学与网络药理学揭示提取物抗呼吸道合胞病毒的机制
Int J Mol Sci. 2025 May 29;26(11):5244. doi: 10.3390/ijms26115244.

本文引用的文献

1
Cost-effectiveness of Prefusion F Protein-based Vaccines Against Respiratory Syncytial Virus Disease for Older Adults in the United States.基于融合前 F 蛋白的疫苗预防美国老年人呼吸道合胞病毒病的成本效益分析。
Clin Infect Dis. 2024 May 15;78(5):1328-1335. doi: 10.1093/cid/ciad658.
2
Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.《妊娠期使用辉瑞呼吸道合胞病毒疫苗预防婴儿呼吸道合胞病毒相关下呼吸道疾病：免疫实践咨询委员会建议-美国，2023 年》。
MMWR Morb Mortal Wkly Rep. 2023 Oct 13;72(41):1115-1122. doi: 10.15585/mmwr.mm7241e1.
3
AAV-based in vivo gene therapy for neurological disorders.基于腺相关病毒的神经疾病体内基因治疗。
Nat Rev Drug Discov. 2023 Oct;22(10):789-806. doi: 10.1038/s41573-023-00766-7. Epub 2023 Sep 1.
4
Respiratory Syncytial Virus Infection: An Update.呼吸道合胞病毒感染：最新进展。
Indian J Pediatr. 2023 Dec;90(12):1245-1253. doi: 10.1007/s12098-023-04613-w. Epub 2023 Jun 16.
5
Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants.孕期接种二价融合前F疫苗预防婴儿呼吸道合胞病毒疾病
N Engl J Med. 2023 Apr 20;388(16):1451-1464. doi: 10.1056/NEJMoa2216480. Epub 2023 Apr 5.
6
Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults.一种二价呼吸道合胞病毒预融合F疫苗在老年人中的疗效和安全性
N Engl J Med. 2023 Apr 20;388(16):1465-1477. doi: 10.1056/NEJMoa2213836. Epub 2023 Apr 5.
7
Combination Ad26.RSV.preF/preF protein vaccine induces superior protective immunity compared with individual vaccine components in preclinical models.在临床前模型中，Ad26.RSV.preF/前F蛋白联合疫苗比单一疫苗成分诱导出更强的保护性免疫。
NPJ Vaccines. 2023 Mar 23;8(1):45. doi: 10.1038/s41541-023-00637-7.
8
Efficacy and Safety of an Ad26.RSV.preF-RSV preF Protein Vaccine in Older Adults.Ad26.RSV.preF-RSV 预 F 蛋白疫苗在老年人中的疗效和安全性。
N Engl J Med. 2023 Feb 16;388(7):609-620. doi: 10.1056/NEJMoa2207566.
9
Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.老年人呼吸道合胞病毒预融合F蛋白疫苗
N Engl J Med. 2023 Feb 16;388(7):595-608. doi: 10.1056/NEJMoa2209604.
10
RSV pre-fusion F protein enhances the G protein antibody and anti-infectious responses.呼吸道合胞病毒融合前F蛋白增强G蛋白抗体和抗感染反应。
NPJ Vaccines. 2022 Dec 19;7(1):168. doi: 10.1038/s41541-022-00591-w.